Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20850496 | 0.87 | SCN1A (0.38) | POLBGAAGFERADRA1A | |
| SCHEMBL10267465 | 0.81 | NR1I2 (0.41) | POLBGAAGFER | |
| SCHEMBL21361482 | 0.80 | L3MBTL1 (0.45) | NPC1RAB9ALPAR1LMNAACHE | |
| SCHEMBL20254372 | 0.79 | NFE2L2 (0.36) | — | |
| SCHEMBL30033430 | 0.79 | ACHE (0.58) | POLBGAAGFERNPC1RAB9A | |
| SCHEMBL196752 | 0.79 | ACHE (0.58) | POLBGAAGFERNPC1RAB9A | |
| SCHEMBL17629451 | 0.79 | ACHE (0.58) | POLBGAAGFERNPC1RAB9A | |
| SCHEMBL15801259 | 0.78 | GAA (0.39) | POLBGAAGFER | |
| Methoxymethane SCHEMBL901280 | 0.77 | ACHE (0.56) | POLBGAAGFERNPC1RAB9A | |
| SCHEMBL13698776 | 0.76 | PDE2A (0.46) | POLBGAAGFERRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130343-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | INHIBIKASE THERAPEUTICS, INC. | 2021-05-06 | — | — | US | disclosed |
| US-20180057488-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | INHIBIKASE THERAPEUTICS, INC. | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180057488-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | MAP3K1, PACSIN2, MAP3K3 | POLB 654/4885GAA 2261/4885GFER 4529/4885 |
| US-20210130343-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | MAP3K1, PACSIN2, MAP3K3 | POLB 654/4885GAA 2261/4885GFER 4529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.